Literature DB >> 15766716

A cell-based cGMP assay useful for ultra-high-throughput screening and identification of modulators of the nitric oxide/cGMP pathway.

Frank Wunder1, Johannes-Peter Stasch, Joachim Hütter, Cristina Alonso-Alija, Jörg Hüser, Emanuel Lohrmann.   

Abstract

We have established a rapid, homogeneous, cell-based, and highly sensitive assay for guanosine 3'-5'-cyclic monophosphate (cGMP) that is suitable for fully automated ultra-high-throughput screening. In this assay system, cGMP production is monitored in living cells via Ca2+ influx through the olfactory cyclic nucleotide-gated cation channel CNGA2, acting as the intracellular cGMP sensor. A stably transfected Chinese hamster ovary (CHO) cell line was generated recombinantly expressing soluble guanylate cyclase, CNGA2, and aequorin as a luminescence indicator for the intracellular calcium concentration. This cell line was used to screen more than 900,000 compounds in an automated ultra-high-throughput screening assay using 1536-well microtiter plates. In this way, we have been able to identify BAY 58-2667, a member of a new class of amino dicarboxylic acids that directly activate soluble guanylate cyclase. The assay system allows the real-time cGMP detection within living cells and makes it possible to screen for activators and inhibitors of enzymes involved in the nitric oxide/cGMP pathway.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15766716     DOI: 10.1016/j.ab.2004.12.025

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  14 in total

Review 1.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.

Authors:  Oleg V Evgenov; Pál Pacher; Peter M Schmidt; György Haskó; Harald H H W Schmidt; Johannes-Peter Stasch
Journal:  Nat Rev Drug Discov       Date:  2006-09       Impact factor: 84.694

Review 2.  Cell-based assays for high-throughput screening.

Authors:  W Frank An; Nicola Tolliday
Journal:  Mol Biotechnol       Date:  2010-06       Impact factor: 2.695

Review 3.  Contemporary Approaches to Modulating the Nitric Oxide-cGMP Pathway in Cardiovascular Disease.

Authors:  Jan R Kraehling; William C Sessa
Journal:  Circ Res       Date:  2017-03-31       Impact factor: 17.367

Review 4.  Stimulators and activators of soluble guanylate cyclase for urogenital disorders.

Authors:  Fabiola Z Mónica; Edson Antunes
Journal:  Nat Rev Urol       Date:  2017-11-14       Impact factor: 14.432

Review 5.  Measurement of NO in biological samples.

Authors:  C Csonka; T Páli; P Bencsik; A Görbe; P Ferdinandy; T Csont
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

Review 6.  The Role of Nitroglycerin and Other Nitrogen Oxides in Cardiovascular Therapeutics.

Authors:  Sanjay Divakaran; Joseph Loscalzo
Journal:  J Am Coll Cardiol       Date:  2017-11-07       Impact factor: 24.094

Review 7.  Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Authors:  A Dasgupta; L Bowman; C L D'Arsigny; S L Archer
Journal:  Clin Pharmacol Ther       Date:  2014-11-28       Impact factor: 6.875

8.  Insights into BAY 60-2770 activation and S-nitrosylation-dependent desensitization of soluble guanylyl cyclase via crystal structures of homologous nostoc H-NOX domain complexes.

Authors:  Vijay Kumar; Faye Martin; Michael G Hahn; Martina Schaefer; Jonathan S Stamler; Johannes-Peter Stasch; Focco van den Akker
Journal:  Biochemistry       Date:  2013-05-07       Impact factor: 3.162

9.  A high-throughput screening strategy for accurate quantification of menaquinone based on fluorescence-activated cell sorting.

Authors:  Yan Liu; Zheng-Lian Xue; Shao-Peng Chen; Zhou Wang; Yong Zhang; Wei-Liang Gong; Zhi-Ming Zheng
Journal:  J Ind Microbiol Biotechnol       Date:  2016-03-21       Impact factor: 3.346

10.  Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation.

Authors:  L S Hoffmann; P M Schmidt; Y Keim; S Schaefer; H H H W Schmidt; J P Stasch
Journal:  Br J Pharmacol       Date:  2009-05-18       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.